Company Interview / High hopes, higher revenue for this small cap

Key Points

- ECS Botanics (ASX:ECS) hits operational cash flow milestone with $1.6 million improvement

- Strategic shift from B2B to B2C drives 20% quarter-on-quarter revenue growth

- Launch of value brand Our Sun leverages outdoor cultivation cost advantages

- Expansion plans target European markets and diversification into capsules and advanced products

ECS Botanics (ASX:ECS) marks a significant milestone at the start of FY26, achieving positive operating cash flow for the first time since 2023. Nan-Maree Schoerie notes that this turnaround follows a strategic pivot from a strictly B2B model to an emphasis on branded B2C offerings, launched approximately 12 months ago. She highlights 20% quarter-on-quarter revenue growth and a $1.6 million net operating cash flow improvement, crediting this progress to focused brand development and operational changes.

Schoerie points to industry dynamics in the medicinal cannabis market, stating the move to direct-to-consumer brands helps ECS Botanics build stronger brand equity in a crowded field. By leveraging the company’s outdoor cultivation capabilities, ECS Botanics has been able to launch a successful value brand, Our Sun, meeting market demand for lower-cost yet high-quality products. She says ECS Botanics is now among the top ten brands in Australia, up from 100 competitors a year ago.

Operational efficiency remains a priority. Schoerie outlines recent investments in premium infrastructure, such as underfloor heating and lighting, have now wound down, enabling greater cost control. Looking ahead, ECS Botanics targets asset optimisation, further European expansion with a new operation in Poland, and product diversification, particularly in capsules and new technologies like VC soap for higher bioavailability.